Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.

Federal infrastructure spending should help the Zacks Building Products - Concrete & Aggregates industry players like VMC and MLM. Yet, high rates and expenses are risks.

REE Automotive Ltd. (NASDAQ:REE ) Q4 2024 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Dana Rubinstein - Chief Strategy Officer Daniel Barel - Co-Founder and Chief Executive Officer Hai Aviv - Chief Financial Officer Conference Call Participants Poe Fratt - Alliance Global Partners Operator Good day and thank you for standing by.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148691&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Ultra Clean Holdings, Inc. (NASDAQ:UCTT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ultra-clean-holdings-inc-lawsuit-submission-form?prid=148692&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

BP's shares surged on takeover speculation in May and the company submitted decent Q1 earnings last month, despite lower liquids realizations. BP generated fairly stable results in oil production in the first-quarter and continued to spend a lot of money on buybacks. The energy giant also has a long term capital framework that calls for capital returns equal to 30-40% of its operating cash flow.

Dynatrace, Inc. DT posted better-than-expected fourth-quarter earnings and issued strong guidance on Wednesday.

TJX stands out as the stronger off-price retail investment, thanks to its global reach, consistent earnings growth, and superior stock performance.

HeartCore Enterprises, Inc. (HTCR) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 12.

TSMC is poised to gain market share from Samsung, with potential collaborations with US chip giants further strengthening its position. Despite gross margin pressures, TSMC's profitability has exceeded expectations, leading me to upgrade my long term gross margin outlook to 57%-59%. Reduced geopolitical risks and attractive valuations suggest potential for multiple expansion, making a compelling case for undervaluation of TSM stock.

Alibaba Group (NYSE:BABA ) Q4 2025 Earnings Conference Call May 15, 2025 7:30 AM ET Company Participants Lydia Liu - Head of Investor Relations Eddie Wu - Chief Executive Officer Toby Xu - Chief Financial Officer Jiang Fan - Chief Executive Officer of Alibaba E-Commerce Business Group Conference Call Participants Gary Yu - Morgan Stanley Alex Yao - JPMorgan Ronald Keung - Goldman Sachs Kenneth Fong - UBS Joyce Ju - Bank of America Alicia Yap - Citigroup Operator Good day, ladies and gentlemen. Thank you for standing by.

Investors need to pay close attention to BWEN stock based on the movements in the options market lately.

CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability.

Exelon (EXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Equity investors continue wondering when small-cap stocks and ETFs will finally garner some momentum. That moment could be nearing.